Current Neuro-Oncology

Volume 27 Number 36
31 December 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 36, 31 December

Campino GA, Shrot S, Constantini S, Roth J, Toren A, Lurye M, Yalon-Oren M.
Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation.
Childs Nerv Syst. 2025 Dec 21;41(1):429. doi: 10.1007/s00381-025-07084-w. PMID: 41423525. Case report. ˍ

van den Bent MJ, Ghisai SA, Wick W, Sanson M, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Tabouret E, Gill S, Griffin M, Taal W, Rudà R, Weller M, McBain C, Reijneveld JC, Enting RH, Tran S, Lesimple T, Kocher M, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Hoogstrate Y, Nuyens S, Golfinopoulos V, Tesileanu CMS, Gorlia T, French P, Baumert BG.
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
Lancet Oncol. 2025 Dec 22;27(1):45-56. doi: 10.1016/S1470-2045(25)00614-X. PMID: 41449147. Interventional study˰ ˍ

Zhou WT, Wu T, Lu YF, Du SX, Zhao HG, Ren SK, Zhao C, Tian YJ, Zhao F.
Development of an integrated risk stratification model for metastatic medulloblastoma (M2/3) using clinical, radiologic, and molecular variables.
Neurooncol Adv. 2025 Dec 22;8(1):vdaf265. doi: 10.1093/noajnl/vdaf265. PMID: 41727341. Observational study. ˍ

Evers Smith JW, Alzate JD, Power L, Wei W, Chao ST, Siddiq M, Prayson R, Barnett GH, Mohammadi AM, Grabowski MM, Suh JH, Murphy ES, Yu JS, Balagamwala E, Neyman G, Stevens GHJ, Peereboom D, Dhawan A, Angelov L.
The impact of the molecular and genetic properties of glioblastoma on patient outcomes following stereotactic radiosurgery at recurrence.
J Neurooncol. 2025 Dec 23;176(2):132. doi: 10.1007/s11060-025-05367-5. PMID: 41432822. Observational study˰ ˍ

Pinson H, De Rudder C, De Backer L, Van Sinay A, Boterberg T, Hallaert G.
Temporal muscle measurements as predictor for outcome in a cohort of IDH-wildtype glioblastoma patients.
Brain Spine. 2025 Dec 23;6:105914. doi: 10.1016/j.bas.2025.105914. PMID: 41551865. ˍ

Sener U, Galloway T, Neth B, Uhm J, Kizilbash SH, Campian JL, Caron S, Breen WG, Lehrer E, Golembiewski E, Schultz S, Hughes H, Steinmetz S, Geyer S, Mead-Harvey C, Huebert C, Tauer W, Mason C, Burns TC, Pritchett J, Haddad T.
Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy.
Contemp Clin Trials Commun. 2025 Dec 23;49:101593. doi: 10.1016/j.conctc.2025.101593. PMID: 41567708. Trial registration ID: NCT06625047. ˍ

Arcos-Montoya D, García-López P, Wegman-Ostrosky T, Camacho-Arroyo I, Valdés-Rives SA, Bello-Alvarez C, Manjarrez-Marmolejo J, De La Fuente-Granada M, Ordaz-Ramos A, Ávila-González D, Díaz NF, Guadarrama-Rangel CF, Navarrete AMB, Aboud O, Cantú-de-León DF, Cacho-Díaz B, González-Arenas A.
Assessing progesterone receptor modulation in glioblastoma: from in vitro and animal model to a human pilot protocol.
Cancer Biol Ther. 2025 Dec 24;27(1):2603095. doi: 10.1080/15384047.2025.2603095. PMID: 41439468. Interventional study. ˍ

Nåhls NS, Anttonen A, Kitti P, Leskelä RL, Akrén O, Saarto T, Carpén T.
Early palliative care decision in patients with primary brain tumor reduces emergency department visits and hospitalization at the end of life.
J Neurooncol. 2025 Dec 24;176(2):137. doi: 10.1007/s11060-025-05377-3. PMID: 41442055. Observational study. ˍ

Ji M, Tian D, Qi Q, Zhao L, Tan P, Lin P, Li Q, Wu J, Lai Y, Cheng Y, Yang H, Ma H.
Analytical Insights into the Epidemiology of Glioma and Treatment Modalities.
World Neurosurg. 2025 Dec 26:124757. doi: 10.1016/j.wneu.2025.124757. PMID: 41456753. Observational study. ˍ

Suryadevara CM, Donaldson H, Khan HA, Groff KJ, Kim CD, Dogra S, Gautreaux J, Roberts LG, Young MG, Snuderl M, Zagzag D, William CM, McFaline-Figueroa JR, Pilar Guillermo Prieto Eibl MD, Cordova CA, Kurz S, Barbaro M, Placantonakis DG.
Neoadjuvant PD1 blockade with laser interstitial thermal therapy for recurrent high-grade glioma.
J Clin Neurosci. 2025 Dec 27;145:111823. doi: 10.1016/j.jocn.2025.111823. PMID: 41456377. Observational study. ˍ

Keric N, Krenzlin H, Lange F, Dauth A, Freyschlag CF, Schnellg O, Misch M, von der Brelie C, Gempt J, Krigers A, Wagner A, Mielke D, Sommer C, Brockmann MA, Meyer B, Rohde V, Vajkoczy P, Beck J, Thomé C, Ringel F.
Treatment differences in IDH-wildtype glioma - the impact of surgery and adjuvant therapy.
J Neurooncol. 2025 Dec 29;176(2):145. doi: 10.1007/s11060-025-05368-4. PMID: 41466163. Observational study. ˍ

Mueller T, Vasella F, Velz J, Voglis S, Akeret K, Padevit L, Schubert M, Weller J, Brüningk S, Rushing E, Sarnthein J, Gramatzki D, Häni L, Raabe A, Zeitlberger AM, Bozinov O, Le Rhun E, Weller M, Regli L, Neidert MC.
Conditional survival in glioblastoma: The evolution of prognostic factors over time.
Int J Cancer. 2025 Dec 30. doi: 10.1002/ijc.70285. PMID: 41472359. Observational study. ˍ

Neuro-Oncology Clinical Research Program; Camphausen K.
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response After Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma.
medRxiv [Preprint]. 2025 Dec 30:2025.12.23.25342908. doi: 10.64898/2025.12.23.25342908. PMID: 41607658. Trial registration ID: NCT04817254. ˍ

Uthamacumaran A, Horth C, Bareke E, Gravel M, Majewski J.
Cellular reprogramming of H3K27M pediatric high-grade glioma to neuron-like state.
Acta Neuropathol Commun. 2025 Dec 30. doi: 10.1186/s40478-025-02185-8. PMID: 41469740. Laboratory investigation. ˍ

Zhang R, Zhang C, Jiang G, Ren Y, Zhang Y, Niu X.
Clinical Features and Prognostic Indicators for Brainstem Ependymomas : A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
J Korean Neurosurg Soc. 2025 Dec 30. doi: 10.3340/jkns.2025.0117. PMID: 41461149. Observational study. ˍ

Kim H, Gomez A, Dixit KS.
First report of a clinical and radiologic response to vorasidenib in a patient with isocitrate dehydrogenase-mutant brainstem astrocytoma.
Neurooncol Pract. 2025 Dec 31;13(2):428-431. doi: 10.1093/nop/npaf131. PMID: 42111031˰ ˍ

Rodriguez A, Dixit K, O'Hara RM Jr, Vojnic M.
Efficacy of tepotinib in patients with high-grade glioma with MET alterations: A case series.
Neurooncol Pract. 2025 Dec 31;13(2):422-427. doi: 10.1093/nop/npaf130. PMID: 42111027. ˍ